DPYD
Basic information
Region (hg38): 1:97077743-97995000
Links
Phenotypes
GenCC
Source:
- dihydropyrimidine dehydrogenase deficiency (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Dihydropyrimidine dehydrogenase deficiency | AR | Pharmacogenomic | Homozygous/compound heterozygous variants can cause Dihydropyrimidine dehydrogenase deficiency; Severe toxicity can occur with certain medications (eg, 5-fluorouracil), and precautions may be beneficial | Biochemical; Neurologic | 6488556; 2989687; 3335642; 8051923; 7832988; 9254861; 10027340; 10071185; 15303009; 19296131; 20544545; 20803296; 20920994; 21420945; 21553285; 21590448; 22410472; 22754590; 23042115 |
ClinVar
This is a list of variants' phenotypes submitted to
- Dihydropyrimidine dehydrogenase deficiency (5 variants)
- not provided (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the DPYD gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 39 | 44 | ||||
missense | 128 | 138 | ||||
nonsense | 35 | 39 | ||||
start loss | 2 | |||||
frameshift | 53 | 57 | ||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 35 | 38 | ||||
splice region | 6 | 5 | 11 | |||
non coding | 34 | 12 | 43 | 89 | ||
Total | 5 | 128 | 173 | 57 | 44 |
Highest pathogenic variant AF is 0.000118
Variants in DPYD
This is a list of pathogenic ClinVar variants found in the DPYD region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-97077787-C-T | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97077823-T-C | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 12, 2018) | ||
1-97077914-T-C | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97077926-T-A | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97077930-G-T | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97077966-A-C | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 12, 2018) | ||
1-97077976-T-C | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 12, 2018) | ||
1-97078015-T-C | not provided (-) | |||
1-97078065-T-C | not provided (-) | |||
1-97078076-A-G | Dihydropyrimidine dehydrogenase deficiency | Likely benign (Jan 13, 2018) | ||
1-97078124-G-A | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97078193-C-A | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97078196-G-A | Dihydropyrimidine dehydrogenase deficiency | Benign (Jan 13, 2018) | ||
1-97078208-C-T | Dihydropyrimidine dehydrogenase deficiency | Benign (Jan 12, 2018) | ||
1-97078240-T-A | not provided (-) | |||
1-97078303-C-T | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97078311-C-T | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 12, 2018) | ||
1-97078341-A-T | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97078350-C-T | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Apr 27, 2017) | ||
1-97078390-G-A | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97078403-C-T | Dihydropyrimidine dehydrogenase deficiency | Benign (Jan 13, 2018) | ||
1-97078473-T-A | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97078500-C-T | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97078518-A-T | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-97078544-A-T | Dihydropyrimidine dehydrogenase deficiency | Uncertain significance (Jan 13, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
DPYD | protein_coding | protein_coding | ENST00000370192 | 23 | 843307 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.37e-22 | 0.103 | 124125 | 10 | 1613 | 125748 | 0.00647 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.217 | 569 | 555 | 1.03 | 0.0000294 | 6700 |
Missense in Polyphen | 220 | 215.85 | 1.0192 | 2598 | ||
Synonymous | -0.374 | 204 | 197 | 1.03 | 0.0000109 | 2024 |
Loss of Function | 1.52 | 40 | 51.8 | 0.772 | 0.00000267 | 621 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00260 | 0.00260 |
Ashkenazi Jewish | 0.00506 | 0.00507 |
East Asian | 0.00245 | 0.00245 |
Finnish | 0.0244 | 0.0244 |
European (Non-Finnish) | 0.00633 | 0.00632 |
Middle Eastern | 0.00245 | 0.00245 |
South Asian | 0.00624 | 0.00616 |
Other | 0.00441 | 0.00441 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil.;
- Pathway
- Pyrimidine metabolism - Homo sapiens (human);beta-Alanine metabolism - Homo sapiens (human);Pantothenate and CoA biosynthesis - Homo sapiens (human);Drug metabolism - other enzymes - Homo sapiens (human);Fluoropyrimidine Pathway, Pharmacokinetics;Carnosinuria, carnosinemia;Ureidopropionase deficiency;GABA-Transaminase Deficiency;Pyrimidine Metabolism;Beta-Alanine Metabolism;UMP Synthase Deiciency (Orotic Aciduria);MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy);Beta Ureidopropionase Deficiency;Dihydropyrimidinase Deficiency;Fluoropyrimidine Activity;pyrimidine ribonucleosides degradation;TYROBP Causal Network;Pyrimidine metabolism;Pyrimidine catabolism;Nucleobase catabolism;Metabolism of nucleotides;Metabolism;uracil degradation;thymine degradation;Pyrimidine nucleotides nucleosides metabolism
(Consensus)
Recessive Scores
- pRec
- 0.386
Intolerance Scores
- loftool
- 0.110
- rvis_EVS
- 1.43
- rvis_percentile_EVS
- 95.02
Haploinsufficiency Scores
- pHI
- 0.300
- hipred
- Y
- hipred_score
- 0.544
- ghis
- 0.490
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.931
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Dpyd
- Phenotype
- reproductive system phenotype; skeleton phenotype;
Gene ontology
- Biological process
- purine nucleobase catabolic process;pyrimidine nucleobase catabolic process;thymine catabolic process;uracil catabolic process;thymidine catabolic process;beta-alanine biosynthetic process;pyrimidine nucleoside catabolic process;oxidation-reduction process
- Cellular component
- cytoplasm;cytosol
- Molecular function
- uracil binding;NADH dehydrogenase activity;dihydrouracil dehydrogenase (NAD+) activity;protein binding;dihydropyrimidine dehydrogenase (NADP+) activity;protein homodimerization activity;metal ion binding;flavin adenine dinucleotide binding;NADP binding;iron-sulfur cluster binding;4 iron, 4 sulfur cluster binding